Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Heart Failure V: Medical Management

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...

Heart Failure IV: Classification and Diagnostic Evaluation

Heart Failure IV: Classification and Diagnostic Evaluation

Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...

Cardiomyopathy V: Interprofessional Care

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...

Heart Failure Drugs: β-Blockers

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...

Heart Failure VI: Adjunct Therapies

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.

Heart Failure II: Pathophysiology

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

AHA/ACC/ESC/WHF Expert Consensus Document: Second Universal Definition of Heart Failure (2026).

Global heart·2026

Same author

Provider Preferences About a Polypill for Heart Failure With Reduced Ejection Fraction: Development of a Multicenter Physician Survey Containing a Discrete Choice Experiment.

Journal of cardiac failure - intersections·2026

Same author

AHA/ACC/ESC/WHF Expert Consensus Document: Second Universal Definition of Heart Failure (2026).

European heart journal·2026

Same author

AHA/ACC/ESC/WHF Expert Consensus Document: Second Universal Definition of Heart Failure (2026).

Circulation·2026

Same author

AHA/ACC/ESC/WHF Expert Consensus Document: Second Universal Definition of Heart Failure (2026).

Journal of the American College of Cardiology·2026

Same author

Association between charcoal cooking fuel and cardiovascular disease prevalence in Haiti: a cross-sectional analysis.

Environmental health : a global access science source·2026

Search research articles

Related Experiment Video

Updated: Jan 15, 2026

Author Spotlight: Workflow for Integrating POCUS Data into EHR for Managing Heart Failure Patients

Author Spotlight: Workflow for Integrating POCUS Data into EHR for Managing Heart Failure Patients

Published on: July 12, 2024

Developing a Multilevel Polypill Implementation Bundle for Patients With Heart Failure With Reduced Ejection

Justin C Chen¹, Colette DeJong², Mansi Agarwal³

¹Department of Medicine, Washington University in St. Louis School of Medicine, St. Louis, Missouri, USA.

|October 9, 2025

Summary

This summary is machine-generated.

A new polypill strategy for heart failure with reduced ejection fraction (HFrEF) can improve patient outcomes. This study identified key factors and developed an implementation bundle to guide its use in HFrEF care.

Keywords:

fixed-dose combination pill heart failure with reduced ejection fraction implementation mapping implementation science polypill

More Related Videos

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

Published on: February 13, 2021

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF

Published on: March 29, 2024

Related Experiment Videos

Last Updated: Jan 15, 2026

Author Spotlight: Workflow for Integrating POCUS Data into EHR for Managing Heart Failure Patients

Author Spotlight: Workflow for Integrating POCUS Data into EHR for Managing Heart Failure Patients

Published on: July 12, 2024

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

Published on: February 13, 2021

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF

Published on: March 29, 2024

Area of Science:

Cardiology
Implementation Science
Health Services Research

Background:

Polypills containing guideline-directed medical therapies for heart failure with reduced ejection fraction (HFrEF) show promise for improving patient outcomes.
However, the factors influencing the successful implementation of polypill-based strategies for HFrEF remain largely unknown.

Purpose of the Study:

To identify determinants impacting polypill-based strategies for HFrEF.
To design a multilevel implementation bundle for HFrEF polypills.
To illustrate how this bundle can enhance patient outcomes.

Main Methods:

A convergent parallel mixed methods study was conducted with patients (N=9) and providers (N=22) at two institutions.
The Consolidated Framework for Implementation Research v2.0 guided data collection on polypill-based HFrEF care.
A matching tool and mechanism mapping were used to develop the implementation bundle.

Main Results:

Four key themes emerged from stakeholder interviews, including the current state of HFrEF care, awareness of innovations, assessing innovation appropriateness, and building competency.
These themes informed the development of a 7-domain multilevel HFrEF polypill implementation bundle.
A directed acyclic graph illustrates the potential impact of the bundle on patient outcomes.

Conclusions:

A multilevel HFrEF polypill implementation bundle was developed.
This bundle offers a framework for improving HFrEF care, particularly in undertreated populations.
Further tailoring of the bundle can optimize its global application.